TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17926822

Group type: EXPERIMENTAL
Intervention: Entecavir (0.5 mg/day for treatment-naive patients, 1 mg/day for patients with lamivudine failure)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lamivudine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Entecavir
Number of subjects: 0
Study: 15545858

Group type: EXPERIMENTAL
Intervention: Tympanometric findings (type B tympanogram)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tympanocentesis (TAP)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Otoscopy and tympanometry
Number of subjects: 90
Study: 11782044

Group type: EXPERIMENTAL
Intervention: Numerical imputation strategies (last observation carried forward, mean and regression based methods)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-parametric strategies (rank and dichotomization based methods)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mean of the other group or counted as treatment failures after dichotomization of the endpoint
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No adequate recommendations can be given
Number of subjects: 0
Study: 9289526

Group type: EXPERIMENTAL
Intervention: Nabumetone (1-2 g once a day)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Aceclofenac (100 mg two times each day)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 274

Group type: COMPARATOR
Intervention: Aceclofenac
Number of subjects: 274
Study: 8295814

Group type: EXPERIMENTAL
Intervention: Clarithromycin oral suspension (7.5 mg/kg; maximum, 500 mg)
Number of subjects: 379

Group type: COMPARATOR
Intervention: Cefaclor oral suspension (20 mg/kg; maximum, 500 mg)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 379

Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Clarithromycin and cefaclor
Number of subjects: 379
Study: 3771808

Group type: COMPARATOR
Intervention: 10-day placebo washout
Number of subjects: 45
Study: 31654501

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept and focal/grid laser photocoagulation
Number of subjects: 22
Study: 28679200

Group type: EXPERIMENTAL
Intervention: INTELLiVENT‐ASV®
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional ventilation modes
Number of subjects: 60
Study: 27623561

Group type: EXPERIMENTAL
Intervention: Transcranial Doppler Ultrasound (TCD) rescreening
Number of subjects: 3840

Group type: EXPERIMENTAL
Intervention: STOP Protocol (combination of risk stratification with TCD and selective chronic red cell transfusion)
Number of subjects: 3840
Study: 24966408

Group type: EXPERIMENTAL
Intervention: Natural banana odor
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Artificial banana odor
Number of subjects: 61

Group type: COMPARATOR
Intervention: Water (no odor)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Active sniffing of banana odors
Number of subjects: 61
Study: 22383124

Group type: EXPERIMENTAL
Intervention: Near-peer teaching
Number of subjects: 558
Study: 20525999

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/day, n = 24)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day, n = 24)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Combination of Ezetimibe and Simvastatin (n = 24)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/day)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Combination therapy (Ezetimibe + Simvastatin)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day)
Number of subjects: 72
Study: 18210156

Group type: EXPERIMENTAL
Intervention: Genetic variants in IGFBP2 and IGFBP5
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genotyping of 34 single nucleotide polymorphisms (SNPs)
Number of subjects: 0
Study: 16356293

Group type: EXPERIMENTAL
Intervention: Depression Recurrence Prevention (DRP) program (n=112)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Combination of the DRP program with psychiatric consultation (PC+DRP, n=39)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Combination with brief cognitive behavior therapy (CBT+DRP, n=44)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Care as usual (CAU, n=72)
Number of subjects: 267
Study: 12727966

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d) with N(G)-monomethyl-L-arginine infusion
Number of subjects: 60
Study: 10783546

Group type: EXPERIMENTAL
Intervention: Computerized version of the Job Descriptive Index (JDI) scales
Number of subjects: 2286

Group type: COMPARATOR
Intervention: Paper-and-pencil version of the Job Descriptive Index (JDI) scales
Number of subjects: 2286
Study: 8778585

Group type: EXPERIMENTAL
Intervention: Recombinant hirudin
Number of subjects: 12142

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 12142
Study: 1317910

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 32

Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combination therapy (Chlorthalidone + Clonidine)
Number of subjects: 32
Study: 3937815

Group type: EXPERIMENTAL
Intervention: Semi‐Euglucon N 1.75 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Daonil N 1.75 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Semi‐Euglucon 2.5 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Daonil 2.5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both HB 420 preparations
Number of subjects: 8

Group type: COMPARATOR
Intervention: Both HB 419 preparations
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: HB 420 preparations
Number of subjects: 8

Group type: COMPARATOR
Intervention: Other HB 419 preparation
Number of subjects: 8
Study: 31219698

Group type: EXPERIMENTAL
Intervention: Growth Mind-Set Single-Session Intervention (GM-SSI)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Computer-based active control program (teaching healthy sexual behaviors)
Number of subjects: 222
Study: 28814418

Group type: EXPERIMENTAL
Intervention: MatchedFlicker programme
Number of subjects: 100

Group type: COMPARATOR
Intervention: Stereo viewer
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Duplicate image pairs
Number of subjects: 100
Study: 27293194

Group type: EXPERIMENTAL
Intervention: Voxtalisib (50 mg BID) in combination with rituximab
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Voxtalisib (50 mg BID) in combination with rituximab+bendamustine
Number of subjects: 37
Study: 25922233

Group type: EXPERIMENTAL
Intervention: Aprepitant group (5-HT3-receptor antagonist + dexamethasone + aprepitant or fosaprepitant)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Control group (5-HT3-receptor antagonist + dexamethasone)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Aprepitant group
Number of subjects: 413

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 413
Study: 23619375

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Usual care-reduced measurement (UC-RM)
Number of subjects: 144
Study: 20886400

Group type: EXPERIMENTAL
Intervention: Fluoroscopy during oral double-balloon enteroscopy (DBE)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Nonfluoroscopy during oral double-balloon enteroscopy (DBE)
Number of subjects: 156
Study: 17976788

Group type: EXPERIMENTAL
Intervention: Internet-based data entry model for documenting ED overcrowding
Number of subjects: 18
Study: 16393237

Group type: EXPERIMENTAL
Intervention: Fiber intake (quartile 4 vs quartile 1)
Number of subjects: 1520

Group type: EXPERIMENTAL
Intervention: Fiber intake (specifically for proximal colon)
Number of subjects: 1520

Group type: EXPERIMENTAL
Intervention: Processed meat intake (quartile 4 vs quartile 1)
Number of subjects: 1520

Group type: EXPERIMENTAL
Intervention: Chicken intake (quartile 4 vs quartile 1)
Number of subjects: 1520

Group type: COMPARATOR
Intervention: Fat intake
Number of subjects: 1520

Group type: COMPARATOR
Intervention: Total red meat intake
Number of subjects: 1520
Study: 12915873

Group type: EXPERIMENTAL
Intervention: Novel community-based service
Number of subjects: 373

Group type: COMPARATOR
Intervention: Standard regional service
Number of subjects: 373
Study: 10596521

Group type: EXPERIMENTAL
Intervention: Brief motivational interview (MI)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 94
Study: 8709665

Group type: EXPERIMENTAL
Intervention: Remote-simultaneous interpretation
Number of subjects: 49

Group type: COMPARATOR
Intervention: Proximate-consecutive interpretation
Number of subjects: 49
Study: 1833900

Group type: EXPERIMENTAL
Intervention: Amrinone
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Enoximone (1 mg/kg bw)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Enoximone (1.5 mg/kg bw)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Phosphodiesterase inhibitors (general)
Number of subjects: 42
Study: 6213379

Group type: EXPERIMENTAL
Intervention: Topical erythromycin 1.5 percent solution
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Topical clindamycin phosphate 1.0 percent solution
Number of subjects: 66
Study: 30954433

Group type: EXPERIMENTAL
Intervention: Human Growth Hormone (HGH)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 27680881

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 8192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8192
Study: 26371397

Group type: EXPERIMENTAL
Intervention: Vitamin-D sufficiency (VDS)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Vitamin-D deficiency (VDD)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Vitamin-D insufficiency (VDI)
Number of subjects: 398
Study: 24841352

Group type: EXPERIMENTAL
Intervention: Ultrasound (US)‐guided access to the subclavian vein
Number of subjects: 403

Group type: COMPARATOR
Intervention: Internal jugular vein access
Number of subjects: 403

Group type: COMPARATOR
Intervention: Cephalic vein access
Number of subjects: 403

Group type: COMPARATOR
Intervention: Subclavian vein access
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Cost analysis
Number of subjects: 403
Study: 22980373

Group type: EXPERIMENTAL
Intervention: Lisinopril 10mg
Number of subjects: 24
Study: 19578247

Group type: EXPERIMENTAL
Intervention: Once-daily LPV/r 460/115 mg/m(2) plus two NRTIs
Number of subjects: 7

Group type: COMPARATOR
Intervention: Twice-daily LPV/r 230/57.5 mg/m(2) plus two NRTIs
Number of subjects: 7
Study: 17478409

Group type: EXPERIMENTAL
Intervention: Internet and mobile phone-based physical activity program (n = 47)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 77
Study: 15001452

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg daily for the initial 8 weeks, then doubled for the remainder of the study
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 92
Study: 12566891

Group type: EXPERIMENTAL
Intervention: Timolol 0.1% gel
Number of subjects: 210

Group type: COMPARATOR
Intervention: Timolol 0.5% solution
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Comparison of both interventions
Number of subjects: 210
Study: 11738915

Group type: EXPERIMENTAL
Intervention: Curettage of the entire anterior capsule (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Curettage of the nasal half of the anterior capsule (Group B)
Number of subjects: 40
Study: 9039173

Group type: EXPERIMENTAL
Intervention: Tretinoin cream 0.025%
Number of subjects: 32

Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 32
Study: 8519047

Group type: EXPERIMENTAL
Intervention: Nimodipine 30 mg TID orally for 3 months
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Nimodipine 30 mg TID orally for 6 months
Number of subjects: 755
Study: 3459860

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel used twice a day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ordinary toothpaste
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel
Number of subjects: 20
Study: 29273232

Group type: EXPERIMENTAL
Intervention: Water resistance therapy
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Raspberry (tongue and lip trills)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Tongue trills
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Lip trills
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: All exercises
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Objective variables
Number of subjects: 84
Study: 27395349

Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Number of subjects: 8381

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 8381
Study: 25268800

Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon counterpulsation pump (IABP)
Number of subjects: 973

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 973
Study: 22813225

Group type: EXPERIMENTAL
Intervention: Sodium fluoride (NaF) varnish or solution (Treatment A)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Titanium tetrafluoride (TiF(4)) varnish or solution (Treatment B)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo varnish or no treatment (Treatment C)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Titanium tetrafluoride (TiF(4)) formulations
Number of subjects: 13
Study: 20383773

Group type: EXPERIMENTAL
Intervention: Short-Intermittent (SI) protocol: 30 s at 110% of maximal aerobic velocity (MAV) with 30 s recovery at 50%
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Long-Intermittent (LI) protocol: 3 min at 95% of MAV with 3 min recovery at 35%
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Heavy Continuous (HC) protocol: at 83% of MAV
Number of subjects: 9
Study: 19208963

Group type: COMPARATOR
Intervention: Cognitive tasks (auditory frequency and lateralization disjunctive reaction time tasks, silent and audible backward counting, question-response clinical standard task) during sinusoidal earth-vertical axis rotation (EVAR) at 0.02 Hz, 0.05 Hz, and 0.1 Hz
Number of subjects: 29

Group type: COMPARATOR
Intervention: Auditory DRT tasks during EVAR at 0.02 Hz, 0.05 Hz, and 0.1 Hz
Number of subjects: 29
Study: 15693825

Group type: EXPERIMENTAL
Intervention: Vitamin C gum (60 mg, Series I)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vitamin C + carbamide gum (30 mg + 30 mg, Series II)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Non-vitamin C gum (Series I)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vitamin C + carbamide gum (30 mg + 30 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vitamin C gum (30 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No gum (negative control)
Number of subjects: 30
Study: 12622502

Group type: EXPERIMENTAL
Intervention: Nitrous oxide in oxygen
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Lidocaine (20 mg)‐propofol mixture
Number of subjects: 135

Group type: COMPARATOR
Intervention: Propofol alone (control)
Number of subjects: 135
Study: 10333897

Group type: EXPERIMENTAL
Intervention: Low-glycemic index diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-glycemic index diet
Number of subjects: 20
Study: 8624083

Group type: COMPARATOR
Intervention: AF102B (40 mg, tid, po)
Number of subjects: 0

Group type: COMPARATOR
Intervention: AF102B (60 mg, tid, po)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1760811

Group type: EXPERIMENTAL
Intervention: 6 x 10(6) IU or 12 x 10(6) IU Cetus IL-2/m2 by i.v. bolus daily for 5 consecutive days on weeks 1, 3 and 5
Number of subjects: 23
Study: 31362993

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab+MTX
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo+MTX
Number of subjects: 0
Study: 28187726

Group type: EXPERIMENTAL
Intervention: Mothers In Motion (MIM) intervention
Number of subjects: 612

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 612
Study: 26105109

Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 24820046

Group type: EXPERIMENTAL
Intervention: 16 cobalt gray equivalents (CGE) of PBI
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 24 cobalt gray equivalents (CGE) of PBI
Number of subjects: 46

Group type: COMPARATOR
Intervention: Mild radiation complications
Number of subjects: 46
Study: 21394458

Group type: EXPERIMENTAL
Intervention: MC5-A Calmare© device
Number of subjects: 73
Study: 18977274

Group type: EXPERIMENTAL
Intervention: Auditory P300 event‐related potential (ERP) in euthymic bipolar patients
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Performance on Sustained Attention in euthymic bipolar patients
Number of subjects: 62

Group type: COMPARATOR
Intervention: Auditory P300 event‐related potential (ERP) in healthy volunteers
Number of subjects: 62
Study: 17200869

Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (DTI) and tractography (DTT)
Number of subjects: 0
Study: 15195895

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 750 mg daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 11148740

Group type: EXPERIMENTAL
Intervention: Minimally invasive transurethral microwave thermotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical management (alpha-blockade)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant and adjuvant alpha-blocker therapy
Number of subjects: 0
Study: 9537785

Group type: EXPERIMENTAL
Intervention: Allergen challenge in allergic patients
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Methacholine challenge in allergic and non-allergic subjects
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Methacholine stimulation of basophils in vitro
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Nasal lavage fluid analysis
Number of subjects: 2
Study: 8018020

Group type: EXPERIMENTAL
Intervention: methyldopa
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: propranolol
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide‐triamterene
Number of subjects: 21

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study: 2562825

Group type: EXPERIMENTAL
Intervention: Celiprolol 400 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 590600

Group type: EXPERIMENTAL
Intervention: Tinidazole (2 g single dose for 3 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Metronidazole (2 g single dose for 3 days)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 60

Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 60
Study: 31837317

Group type: EXPERIMENTAL
Intervention: Defocus Incorporated Multiple Segments (DIMS) lens
Number of subjects: 20

Group type: COMPARATOR
Intervention: Single vision (SV) lens
Number of subjects: 20
Study: 31203982

Group type: EXPERIMENTAL
Intervention: Exercise (EX) - exercised to expend approximately 15% of digestible energy requirements for 4 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Diet (DIET) - intake restricted to approximately 85% of digestible energy requirements for 4 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both groups (DIET and EX)
Number of subjects: 10
Study: 27287069

Group type: EXPERIMENTAL
Intervention: LM50
Number of subjects: 328

Group type: COMPARATOR
Intervention: LM25
Number of subjects: 328
Study: 26501007

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (500mg orally one hour prior to extraction and 160mg gel foam soaked in tranexamic acid placed into the extraction socket postoperatively)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (crocin orally one hour prior to extraction and gel foam soaked in saline placed into the extraction socket postoperatively)
Number of subjects: 60
Study: 23872699

Group type: EXPERIMENTAL
Intervention: Two-week, self-guided, online, mindfulness-based intervention
Number of subjects: 104

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 104
Study: 21866716

Group type: EXPERIMENTAL
Intervention: Group psychoeducational music therapy songwriting session concerning coping skills
Number of subjects: 89

Group type: COMPARATOR
Intervention: Group psychoeducational session concerning coping skills (Control)
Number of subjects: 89
Study: 19515178

Group type: EXPERIMENTAL
Intervention: Bladder neck obstruction (42 men)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Prostatic obstruction (29 men)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Overall assessment
Number of subjects: 71
Study: 16401736

Group type: EXPERIMENTAL
Intervention: Memantine 20 mg daily
Number of subjects: 175
Study: 15529902

Group type: EXPERIMENTAL
Intervention: Two newsletters per week for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study: 11122287

Group type: EXPERIMENTAL
Intervention: Contralateral turbinectomy
Number of subjects: 26

Group type: COMPARATOR
Intervention: No turbinate surgery
Number of subjects: 26
Study: 9295241

Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: 0.3% tacrolimus ointment
Number of subjects: 213

Group type: COMPARATOR
Intervention: Vehicle alone
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: All tacrolimus groups
Number of subjects: 213
Study: 8313931

Group type: EXPERIMENTAL
Intervention: Deflazacort (DFZ)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Prednisone (PDN)
Number of subjects: 30
Study: 3524226

Group type: EXPERIMENTAL
Intervention: Computer-assisted insulin dosage decision-making (n = 7)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard algorithms for insulin adjustment (n = 9)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study: 30975178

Group type: EXPERIMENTAL
Intervention: suPAR measurement
Number of subjects: 4420

Group type: COMPARATOR
Intervention: Triage alone
Number of subjects: 4420
Study: 28524639

Group type: EXPERIMENTAL
Intervention: IVPM (1000 mg methylprednisolone)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34